Tagged with Boehringer Ingelheim

Singapore The latest healthcare and pharma news from Singapore, including the partnership between Boehringer Ingelheim and A*STAR for targeted cancer therapies, Amgen’s sponsorship of biotech incubator, NSG BioLabs, and Tessa Therapeutics’ USD 126 million funding round.   Boehringer Ingelheim / A*STAR partner on targeted cancer therapies (BioSpectrum Asia) Boehringer Ingelheim and…

Germany The latest from German pharma, including Bayer’s 2021 financial results, the country’s plan to spend $3.14 billion on vaccine capacity to cover Covid-19 outbreaks until 2029, and Boehringer Ingleheim’s case for broader use of its diabetes drug.   Bayer’s 2021 annual report: €44.1 billion revenue, Crop Science grows double digits,…

Germany The latest news from German pharma, including Bayer’s USD 2 billion acquisition of San Diego’s Vividion Therapeutics; Boehringer Ingelheim’s new investment in a Vienna production facility; BioNTech’s plans to inaugurate an mRNA manufacturing network in Africa; and the termination of the GSK/Merck KGaA cancer drug partnership.   German drug giant…

Denmark Data has been collected within Danish healthcare for more than 40 years, extending beyond the national patient registry to include a broad range of data points, from IVF to the birth registry, abortion, the weight and height of children, and much more. Danes tend to have a high level of…

Turkey In the world’s 18th largest market, recent pricing struggles have pushed some companies to revaluate their investment approach. Multinational organizations are complying with localization policies but are divided between having their own plant or partnering with a local CMO provider – although all of them appear to agree on one…

Turkey Boehringer Ingelheim (BI), the largest private pharma company in the world, has become the latest Big Pharma player to commit to Turkish localization after announcing a contract manufacturing partnership with Abdi Ibrahim, the country’s national pharma champion.   The plan is to produce one out of every two boxes of…

Denmark Boehringer Ingelheim’s Nicolas Dumoulin outlines Denmark’s relevance to the German family-owned company, including the strong uptake of its diabetes and COPD medications in the country and its host of research collaborations with local partners.   There is a wealth of knowledge in Denmark, especially in the cardiometabolic area, and a…

Saudi Arabia Boehringer Ingelheim’s Regional Managing Director and Head of Human Pharma in the Middle East, Turkey, and Africa (‘META’) Mohammed Al-Tawil reflects on more than two decades of his career with the organization. Underlining the benefits of being a family-owned company, Tawil explains why Boehringer Ingelheim continues to invest in META,…

Turkey Evren Özlü, General Manager of Turkey and Sub-Saharan Africa at Boehringer Ingelheim, discusses the company’s double-digit growth in the last year, and its leading position as one of the fastest growing pharmaceutical companies in Turkey across Human Pharma and Animal Health. Özlü highlights diabetes and specialty care as the main…

Europe Boehringer Ingelheim’s Hubertus von Baumbach, the newly appointed president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), shares the goals of his presidency and the role of the innovative European pharma industry in building a healthier future for the continent’s citizens in the wake of the COVID-19 pandemic.…

China In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai International Medical Center (SIMC) jointly established a Rehabilitation Medicine Center for stroke patients with the mission to bring and deliver German stroke rehabilitation treatment standards to patients in China.   According to Consanas Rehabilitation, there are…

Boehringer Ingelheim With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the Chinese biotech industry.   Boehringer Ingelheim has its sights set on establishing a deeper rapport with the Chinese biotech sector.…